Biohaven FDA Resubmission Accepted for Ataxia Drug Troriluzole
Biohaven secures FDA acceptance for its troriluzole resubmission in spinocerebellar ataxia and inks a global Kv7 ion channel licensing deal.
Biohaven Ltd. reported a series of regulatory and partnership milestones alongside its third-quarter 2026 financial results, highlighted by the U.S. Food and Drug Administration's acceptance of the company's resubmitted new drug application for Vyglxia, its branded formulation of troriluzole, as a treatment for spinocerebellar ataxia.
The FDA has set a user fee goal date in the first quarter of 2027 for the Vyglxia review, giving Biohaven a clear regulatory timeline for a condition that currently has no approved disease-modifying therapies. Spinocerebellar ataxia is a group of progressive neurological disorders affecting coordination and balance, representing a significant unmet medical need.
Read more DaVita Posts $3.58B in Revenue for Third Quarter 2026 →
Separately, the company announced an exclusive global licensing agreement with South Korea-based SK Biopharmaceuticals Co., Ltd. covering Biohaven's Kv7 ion channel platform. The deal includes opakalim, a compound in the platform's pipeline. Kv7 channel modulators have drawn growing scientific interest for their potential in neurological and other disorders, and the arrangement positions SK Biopharmaceuticals to advance the platform on a worldwide basis.
The dual announcements — a domestic regulatory acceptance and an international licensing partnership — reflect Biohaven's strategy of advancing its neuroscience pipeline through both internal development and external collaborations. The company's quarterly financial results were released alongside these business updates, though the regulatory and commercial developments drew primary attention from analysts tracking the ataxia therapeutic space.
Continue reading at Earnings.
